Glutathione
The body's master endogenous antioxidant tripeptide — foundational redox biology whose supplemental benefits depend heavily on route and formulation.
Glutathione (GSH) is the most abundant intracellular antioxidant tripeptide, synthesized in virtually every cell from cysteine, glutamate, and glycine. It scavenges reactive oxygen species, serves as substrate for glutathione peroxidase and glutathione-S-transferase Phase II detoxification, regenerates vitamins C and E, and maintains the cellular redox balance. While its biochemistry is well established, supplemental glutathione faces a central bioavailability problem: plain oral dosing is poorly absorbed, driving the use of liposomal, intranasal, nebulized, and IV formulations. Clinical evidence is strongest in specific contexts (acetaminophen overdose via the precursor NAC, NAFLD, early Parkinson's disease, cystic fibrosis), while broad wellness, detox, and cosmetic skin-lightening claims outrun the outcome data.
Class
Endogenous antioxidant tripeptide (γ-glutamyl-cysteinyl-glycine)
Half-life
Very short in plasma (~2–5 minutes IV; minutes to tens of minutes); hours for liposomal formulations
Routes
Oral (standard capsule), Oral (liposomal), Oral (S-acetyl-glutathione), Sublingual, Intravenous, Subcutaneous, Intranasal, Nebulized, Topical
Category
Immune & Mitochondrial
Researched benefits
What it's studied for
Master intracellular antioxidant
The reduced GSH thiol group directly neutralizes reactive oxygen species (hydroxyl radicals, peroxynitrite, singlet oxygen) and, more importantly, serves as substrate for glutathione peroxidase enzymes that detoxify hydrogen peroxide and lipid peroxides. This is established, non-controversial biochemistry central to cellular redox homeostasis.
Phase II liver detoxification
As substrate for glutathione-S-transferase enzymes, GSH conjugates electrophilic toxins and xenobiotics — including the acetaminophen metabolite NAPQI, heavy metals, aldehydes, and alcohol byproducts — making them water-soluble for elimination. Depletion of hepatic GSH is what makes acetaminophen overdose lethal, and restoring it (via the precursor NAC) is standard-of-care.
Liver support in fatty liver disease
Oral and IV glutathione have shown improvements in ALT and oxidative-stress markers in NAFLD trials; a Japanese RCT of oral glutathione 300 mg daily for 4 months produced significant ALT reduction versus placebo. Evidence is moderate — stronger than for general wellness use but weaker than established NAFLD interventions like weight loss.
Neuroprotection and Parkinson's research
Parkinson's disease features early depletion of GSH in the substantia nigra. Intranasal delivery bypasses the blood-brain barrier and has shown safety and suggested functional benefit in early PD pilot trials; IV glutathione has been used adjunctively in European neurology clinics. Evidence remains preliminary and it is not an established therapy.
Respiratory support in cystic fibrosis
A meta-analysis of four RCTs of inhaled/nebulized glutathione reported improvement in FEV1 lung function — a disease-specific clinical finding rather than a generic wellness claim. Nebulized delivery targets lung tissue directly.
Immune cell function
Lymphocytes require adequate GSH for proliferation, cytokine production, and antigen response; GSH depletion impairs T- and B-cell function and correlates with disease progression in HIV. Supplementation supports appropriate immune activity without producing immunosuppression, though evidence for fewer infections in healthy users is weak.
Skin brightening and pigmentation
Glutathione inhibits tyrosinase and shifts melanocyte output from dark eumelanin toward lighter pheomelanin. Effects are real but route-dependent and modest with oral/topical use; the more pronounced IV protocols carry documented safety concerns and reverse after discontinuation.
Ferroptosis and mitochondrial protection
GSH is the substrate for GPx4, the primary enzyme preventing ferroptosis (iron-dependent lipid-peroxidation cell death), and mitochondria maintain their own GSH pool that shields the electron transport chain. Mitochondrial GSH depletion is implicated in aging, neurodegeneration, heart failure, and NAFLD.
Mechanism
How it works
Glutathione operates through several distinct mechanisms beyond the simple 'antioxidant' label. Its reduced form (GSH) carries a free thiol (-SH) group on the cysteine residue that can donate an electron to neutralize reactive oxygen species in a fast, enzyme-independent reaction (2 GSH + ROS → GSSG + reduced species). Quantitatively more important is its role as substrate for glutathione peroxidase (GPx) enzymes, which detoxify hydrogen peroxide and organic hydroperoxides (2 GSH + H2O2 → GSSG + 2 H2O). GPx4, a membrane isoform, is the primary defense against ferroptosis. Glutathione is continuously recycled from its oxidized form (GSSG) back to GSH by glutathione reductase using NADPH from the pentose phosphate pathway; the GSH:GSSG ratio (roughly 100:1 in a healthy cell) is one of the most reliable biochemical markers of oxidative stress.
In detoxification, GSH is the substrate for the glutathione-S-transferase (GST) family, which conjugates GSH onto electrophilic toxins, xenobiotics, and reactive metabolites — the acetaminophen metabolite NAPQI, chemotherapy agents, heavy metals like mercury and arsenic, environmental toxins, and endogenous electrophiles such as 4-HNE — rendering them water-soluble for excretion in bile or urine. This is the core of Phase II hepatic detoxification, and its collapse during acute GSH depletion (acetaminophen overdose, certain chemotherapy) drives the resulting cell death.
Beyond passive antioxidant roles, GSH participates in cell signaling through S-glutathionylation, a reversible post-translational modification of protein cysteine residues that regulates transcription factors (NF-κB, AP-1), metabolic enzymes, cytoskeletal proteins, and apoptosis regulators — a regulatory mechanism increasingly compared to phosphorylation. Mitochondria import their own GSH pool to protect Complex I and Complex III from electron-transport ROS leak. In the skin, GSH inhibits tyrosinase, the rate-limiting enzyme of melanin synthesis, shifting output toward lighter pheomelanin.
The central pharmacological challenge is delivery. Plain oral glutathione is largely degraded by gastrointestinal peptidases (historically estimated <5–10% bioavailability), and even absorbed intact GSH crosses cell membranes poorly — most tissue GSH comes from local synthesis using cysteine, glutamate, and glycine as substrates rather than uptake of whole molecules. Intact GSH also does not cross the blood-brain barrier efficiently. This explains why liposomal and S-acetyl formulations, intranasal delivery (bypassing the BBB), nebulization (targeting lung tissue), IV (100% systemic bioavailability but rapid clearance), and precursor supplementation with N-acetylcysteine (NAC, providing rate-limiting cysteine) are all used to raise functional GSH levels.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Most consumer glutathione is pre-formulated (oral capsules, liposomal liquids, sublingual tablets, topical creams) and requires no reconstitution. Injectable, nebulized, and intranasal forms are prepared by 503A compounding pharmacies under sterile (USP 797) procedures: lyophilized USP-grade GSH is reconstituted in preservative-free 0.9% saline to 50–200 mg/mL. Bacteriostatic water (benzyl alcohol) is NOT suitable for IV use. Solutions are stored refrigerated and used within days to weeks; progressive yellowing/darkening can indicate oxidation to GSSG. Insist on a COA showing ≥98% purity and verification of reduced (GSH) versus oxidized (GSSG) state.
Beginner (oral)
- Dose
- 250–500 mg once daily in week 1, titrating to 500–1000 mg daily
- Frequency
- Once daily, or 250 mg twice daily
- Timing
- Morning; empty stomach preferred (with food acceptable if GI upset)
- Duration
- 8–12 week trial before judging benefit
- Route
- Oral (liposomal preferred; standard capsules for low-cost testing)
Best starting point for general wellness/longevity. No acute subjective effect is normal — benefits are gradual (skin, recovery, liver labs over weeks to months). No cycling required.
Intermediate (oral + precursors)
- Dose
- Liposomal GSH 500 mg twice daily plus NAC 600 mg twice daily; optional glycine 3–5 g/day, ALA 300–600 mg/day, selenium 100–200 mcg/day
- Frequency
- Twice daily
- Timing
- With or between meals; combined dosing with other antioxidants is fine
- Duration
- 3–6 months with baseline and follow-up ALT/AST/GGT and oxidative-stress markers
- Route
- Oral
For targeted indications (NAFLD, chronic fatigue, advanced skin protocols). Supporting endogenous synthesis with precursors is often more effective than GSH alone.
GlyNAC protocol
- Dose
- Glycine ~5 g twice daily + NAC ~2.7 g twice daily (study dosing: glycine 1.3 mM/kg/day + NAC 81 mg/kg/day)
- Frequency
- Twice daily, implemented gradually
- Timing
- Divided through the day
- Duration
- 16 weeks in the original trial
- Route
- Oral
Baylor-popularized precursor protocol shown to improve GSH levels, mitochondrial function, insulin resistance, and cognition in older adults. High-load; titrate up slowly.
Intranasal
- Dose
- 100–400 mg per day (25–50 mg per spray)
- Frequency
- 1–2 times daily, 2–4 sprays per nostril
- Timing
- Head tilted slightly forward; prime pump before first daily use
- Duration
- Continuous for CNS/cognitive targets
- Route
- Intranasal
Bypasses the blood-brain barrier for cognitive and Parkinson's applications; a pilot RCT used 200 mg daily over 3 months. Requires compounded sterile spray.
Nebulized
- Dose
- 150–600 mg per session (up to 1500 mg for cystic fibrosis)
- Frequency
- 1–4 times per week
- Timing
- 10–15 minute sessions; rinse mouth afterward
- Duration
- Per respiratory indication
- Route
- Nebulized
Targets lung tissue for chronic bronchitis, post-viral lung recovery, and CF. Pre-medicate with a bronchodilator (e.g. albuterol) if any asthma history — bronchospasm is a real risk. Requires sterile compounded solution and a jet/mesh nebulizer.
IV (advanced, clinical)
- Dose
- 600–2000 mg per session (NAFLD 600 mg; Parkinson's 600–1400 mg; skin lightening 600–1200 mg; chemo adjunct 1500–2500 mg regimen-specific)
- Frequency
- 1–3 times per week during active phase, then tapered
- Timing
- IV push over 10–15 minutes or infusion over 20–30 minutes in preservative-free saline
- Duration
- 8–12 week courses with reassessment
- Route
- Intravenous
Clinical setting only with trained clinician and monitoring — never self-administer. Achieves 100% bioavailability but clears in minutes. Doses >2000 mg (typical of cosmetic clinics) carry FDA safety warnings and diminishing returns.
Topical
- Dose
- 1–5% GSH in cream/gel; pea-sized dab per 10–20 cm²
- Frequency
- 1–2 times daily
- Timing
- Applied to clean skin
- Duration
- 3–6 months for visible change
- Route
- Topical
For facial hyperpigmentation, melasma, and post-inflammatory hyperpigmentation. Best sourced from a compounding pharmacy; patch-test first for contact sensitization.
- Formulation drives everything: bioavailability ranges roughly 5–10% for standard oral GSH, 15–35% liposomal, 20–40% S-acetyl-glutathione, 10–20% sublingual, 10–40% intranasal (with preferential CNS delivery), and 100% IV.
- Dose-response flattens above ~1000 mg daily oral and ~1000–1500 mg per IV session — 'more is better' is false for glutathione.
- NAC (providing rate-limiting cysteine) is frequently more effective and far cheaper than direct GSH at raising cellular glutathione; many protocols combine both.
- Glutathione does not require cycling — there is no known tolerance or withdrawal at typical doses.
- If training adaptation is the goal, consider avoiding high-dose antioxidants immediately before workouts.
- Stop IV/injectable forms 7–14 days and oral forms 2–3 days before elective surgery. Reserve IV as a first experience for specific medical indications, not general wellness.
Evidence
Research & clinical studies (8)
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease
IV glutathione 1,400 mg three times weekly for 4 weeks was well tolerated in Parkinson's patients (n=21) and produced a numerical 2.8-unit improvement in UPDRS motor scores over placebo that did not reach statistical significance, warranting larger trials.
PMID 19230029The systemic availability of oral glutathione
In 7 healthy volunteers, a single 3 g oral dose of glutathione did not significantly raise plasma glutathione, demonstrating negligible systemic bioavailability due to intestinal and hepatic γ-glutamyltransferase hydrolysis.
PMID 1362956Oral glutathione supplementation in nonalcoholic fatty liver disease (Honda et al.)
A Japanese RCT of oral glutathione 300 mg daily for 4 months in NAFLD patients showed significant ALT reduction compared with placebo.
Intranasal glutathione in early Parkinson's disease (Mischley et al.)
A pilot randomized trial of intranasal glutathione 200 mg daily over 3 months demonstrated safety and suggested functional improvement in early Parkinson's disease; later larger trials showed mixed results.
Oral liposomal glutathione bioavailability and oxidative-stress markers (Sinha et al.)
A small trial of ~500 mg liposomal glutathione over 1–2 weeks in 12 subjects reported increased whole-blood, erythrocyte, plasma, and PBMC glutathione markers, reduced oxidative-stress markers, and improved immune parameters.
GlyNAC (glycine + N-acetylcysteine) supplementation in older adults (Kumar et al.)
A Baylor trial of glycine plus NAC for 16 weeks in older adults showed significant improvements in glutathione levels, mitochondrial function, insulin resistance, cognitive function, and multiple aging biomarkers.
Six-month oral glutathione supplementation in healthy adults
A 6-month randomized trial in 54 adults reported increases in blood and cellular glutathione stores, indicating that chronic oral dosing (unlike single doses) can raise measured glutathione pools.
Nebulized glutathione for lung function in cystic fibrosis (meta-analysis)
A meta-analysis of four RCTs reported improvement in FEV1 lung function with inhaled/nebulized glutathione in cystic fibrosis patients.
Combinations
Stacking & blends
GlyNAC
Raise cellular glutathione and improve mitochondrial and metabolic aging biomarkers
Glycine and NAC provide two of the three GSH building blocks (including rate-limiting cysteine), driving endogenous synthesis where it is needed. Clinical trial data show improvements in GSH, mitochondrial function, insulin resistance, and cognition in older adults.
Antioxidant Network Stack
Comprehensive redox support and oxidative-stress reduction
ALA recycles oxidized GSH and other antioxidants, selenium is a GPx cofactor, and vitamins C and E are regenerated by the glutathione system — a biochemically synergistic network rather than isolated single mechanisms.
NAFLD Liver Support
Reduce hepatic oxidative stress and improve liver enzymes in fatty liver disease
Combines GSH restoration with precursor support and complementary hepatoprotective agents; used alongside weight loss (dietary or GLP-1-assisted), which remains the foundation of NAFLD treatment.
Mitochondrial / Chronic Fatigue Protocol
Support mitochondrial function and energy metabolism in fatigue syndromes
Layers glutathione redox protection with electron-transport and NAD+ support; mitochondrial GSH protects Complex I and III from ROS leak while methylene blue and NAD+ precursors address complementary redox systems.
Parkinson's Adjunct
Adjunctive neuroprotective and symptomatic support in early Parkinson's disease
Intranasal GSH bypasses the blood-brain barrier to address substantia-nigra GSH depletion, with precursor and mitochondrial support. Must be used alongside, not instead of, standard PD therapy under neurology supervision.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Known hypersensitivity to glutathione or formulation excipients (liposomes, preservatives, sulfites)
- Active or severe/unstable asthma and reactive airway disease — avoid high-dose nebulized GSH
- Active chemotherapy with platinum agents or alkylators without oncology coordination (GSH may reduce antitumor efficacy while lowering toxicity)
- Pregnancy/lactation — avoid IV and high-dose protocols absent specific medical indication
- Recent solid-organ transplant — discuss with transplant team (theoretical immune interaction)
Glutathione has an exceptionally favorable safety profile at typical oral doses, adding to a vast endogenous pool (1–10 mM). The main safety concerns cluster around parenteral and cosmetic use: the FDA issued a 2019 alert on compounded injectable glutathione after endotoxin-related adverse events, and multiple regulators (Philippines DOH/FDA, EU) have warned against high-dose IV glutathione for skin lightening, citing kidney/liver adverse events and severe skin reactions including Stevens-Johnson syndrome. G6PD deficiency warrants caution (impaired GSH recycling; avoid concurrent oxidant drugs). Never self-administer IV glutathione. Stop and seek evaluation for allergic reactions, persistent bronchospasm, or unexplained liver-enzyme elevation.
FAQ
Glutathione — common questions
Does oral glutathione actually work, or is it destroyed in digestion?
It depends on the formulation. Standard oral GSH has historically low bioavailability (<5–10%) due to gut peptidase degradation, and a single dose barely raises plasma levels. However, liposomal, S-acetyl, and sublingual forms — and longer-duration oral dosing — show measurably higher absorption and can raise blood and cellular glutathione in small studies. For many users, supplying the precursor NAC is equally or more effective than direct GSH.
Is IV glutathione worth the cost compared to oral forms?
For general anti-aging or wellness, usually not. IV achieves 100% bioavailability and high peak plasma levels but clears within minutes, and cellular uptake of intact GSH is limited — most tissues rely on local synthesis. IV may be worth it for specific medical indications (NAFLD, Parkinson's, chemotherapy adjunct) under clinical supervision, but for routine antioxidant support a well-designed oral protocol is more cost-effective.
Can glutathione lighten my skin?
Yes, but the effect is route- and dose-dependent. It inhibits tyrosinase and shifts melanin toward lighter pheomelanin. IV produces the most pronounced lightening; oral is modest (over 3–6 months); topical gives local spot effects. Effects reverse after stopping. The FDA and other regulators have warned specifically against high-dose IV cosmetic protocols due to kidney, liver, and severe skin adverse events.
What's the difference between glutathione and NAC?
NAC (N-acetylcysteine) is a precursor; glutathione is the end product. NAC provides cysteine, the rate-limiting amino acid your cells use to synthesize GSH locally where it's needed. In many contexts NAC is more effective than direct GSH at raising cellular glutathione — and it's cheaper with a larger clinical evidence base. Combining the two (or using the GlyNAC protocol) may be better than either alone.
Does glutathione help with fatty liver disease?
There is moderate evidence. NAFLD involves hepatocyte oxidative stress and mitochondrial dysfunction where GSH is relevant. A Japanese RCT of oral glutathione 300 mg daily for 4 months showed significant ALT reduction, and Italian IV trials showed similar biomarker improvements. It works best as an adjunct to weight loss and metabolic improvement, not as a substitute.
Can glutathione help with Parkinson's disease?
Emerging evidence suggests a possible role, but it is not established treatment. Parkinson's involves early GSH depletion in the substantia nigra; intranasal glutathione bypasses the blood-brain barrier and showed safety and suggested benefit in a pilot RCT, though larger trials are mixed. It may be a reasonable adjunct under neurologist supervision but should never replace standard PD therapy.
Is glutathione safe during chemotherapy?
This requires oncology coordination. Some chemotherapy drugs (cisplatin, oxaliplatin, alkylators) work partly by generating reactive species that GSH can inactivate, so high-dose GSH could theoretically reduce efficacy — while also reducing toxicities like neuropathy and ototoxicity. Never take high-dose or IV glutathione during chemotherapy without explicit oncologist involvement in protocol design.
How long until I notice glutathione working?
Glutathione does not produce acute subjective effects — most users feel 'nothing' for the first 2–4 weeks, which is normal. Skin changes take 4–12 weeks, recovery improvements 2–4 weeks, and liver enzymes or oxidative-stress markers improve over 4–12 weeks on adequate protocols. It's a foundational metabolic support compound, not a stimulant or nootropic.
